Quantifying Cardiovascular-Kidney-Metabolic(CKM) Health Age Using Wearables and lab Biomarkers
Cardiovascular-Kidney-Metabolic (CKM) syndrome represents a growing public health crisis, yet its subclinical heterogeneity remains underexplored. Early detection of physiological deviation is critical for preventing irreversible organ damage. Here, we characterize the prevalence and interplay of CKM impairment in a US cohort (N=819) by integrating continuous wearable data with clinical biomarkers. We assessed cardiovascular, kidney via clinical biomarkers, namely Chol/HDL, eGFR, as well as metabolic health risk through Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). We show that while metabolic and cardiovascular disruptions are significantly associated (r=0.26, $p<0.001$), early-stage kidney impairment manifests independently. Utilizing a normalized deviance score, we identified significant health impairments in 29.0% of the cohort. Cardiovascular deviation was the most prevalent singular phenotype (13.3%), followed by metabolic (9.1%) and renal (6.25%) deviations, with dual metabolic-cardiovascular impairment occurring in only 2.2% of participants. These findings suggest that high system-specific deviance may serve as an indicator for accelerated physiological aging within the respective organ system. Furthermore, Step count, Active Zone Minutes, and resting heart rate were identified as the key wearable predictors of cardiovascular and metabolic decline. Leveraging these and CKM metrics, we developed a Health Age model that tracks physiological health, aligning with established clinical standards (Metabolic syndrome severity and modified AHA Life's Essential 8) and user-reported overall health. These findings underscore the necessity of a multi-system subtyping approach, demonstrating that wearable-derived phenotypes can facilitate the early, targeted interventions required to manage the complex landscape of CKM syndrome.